# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN
- Date: 2026-06-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: modern shifted

## Reason for visit

Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth. **S**

## Historical basis

- Judy Garland was born Frances Ethel Gumm on June 10, 1922, in Grand Rapids, Minnesota, to parents in vaudeville, and first appeared on stage as a small child. **D**
- She was signed by Metro-Goldwyn-Mayer at 13 and became a national star at 17 in The Wizard of Oz. **D**
- As a teenage studio performer she was given stimulant "pep pills" (amphetamines; Benzedrine is named) to suppress her appetite and keep up her energy through long working days, and sleeping pills (barbiturates; Seconal is named) so that she could sleep. She later described being given pills to stay on her feet and then being put to sleep with sleeping pills at the studio hospital. **D**
- Accounts differ on who first gave her the pills. A biography by Gerald Clarke reports that her mother gave her pills for energy and sleep in early childhood, before she joined the studio; other accounts attribute the pills to the studio and its doctors. **R**
- She struggled with dependence on prescribed medicines, stimulants and sleeping pills, for the rest of her life; by her twenties she was already dependent on pills. **D**
- Suicide attempts were reported publicly, including one in 1950; a biographical encyclopedia describes others in the 1940s and early 1950s. **D**
- In her twenties she was treated for what was publicly called exhaustion and spent periods in hospitals and sanitariums, including a stay at Peter Bent Brigham Hospital in Boston in 1949. **D**
- Her contract with Metro-Goldwyn-Mayer ended in 1950, and she returned to the stage in concert. **D**
- She starred in A Star Is Born, released in 1954, and was nominated for the Academy Award for Best Actress. **D**
- She gave birth to her third child, a son, in March 1955. **D**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- She wants to stop needing pills to sleep and to work, without being made to feel she is to blame for them. **S**
- She is afraid of being unable to sleep or perform during the change. **S**
- She worries about her weight if she stops the stimulant. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine **S**
- Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy **S**
- Sertraline 25 mg oral tablet, one tablet daily **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- by 1939: Stimulant pills for appetite and energy and barbiturate sleeping pills given to her as a teenage studio performer, with dependence on prescribed medicines since **D** (CLM-0003, CLM-0005)
- 1949: Hospital and sanitarium stays in her twenties, publicly described as treatment for exhaustion **D** (CLM-0007)
- 1950: Suicide attempts reported publicly, including one in 1950; recorded without detail **D** (CLM-0006)
- March 1955: Birth of her third child three months before the index visit **D** (CLM-0010)

## Procedures and immunizations

- 2026-06-22 to 2026-06-22: Twelve-lead electrocardiogram before continuing a stimulant **S**
- 2026-06-22: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin: 12.3 g/dL; MCV: 86 fL; Platelets: 284 10*3/uL; Ferritin: 24 ng/mL; Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.66 mg/dL; eGFR (CKD-EPI 2021): 119 mL/min/1.73 m²; Glucose: 82 mg/dL; AST: 21 U/L; ALT: 18 U/L; GGT: 24 U/L; TSH: 1.9 mIU/L; DAST-10: 6; AUDIT-C: 2; PHQ-9: 14; GAD-7: 13. All results are synthetic.

BP 128/84 mmHg; pulse 98 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 46.5 kg; BMI 20.4 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, warm and quick, anxious at first and then candid; speech normal in rate; no signs of intoxication or withdrawal; Mood low and worried; PHQ-9 14 with item 9 scored 0, GAD-7 13; Mood Disorder Questionnaire negative; no thoughts of suicide or self-harm now. Functional status: Independent in all activities; groggy in the mornings and tired in the afternoons; works long days. Physical examination is intentionally limited. **S**

## Safety assessment

Current ideation: absent; intent: absent; plan: absent; access reviewed: yes. Disposition: Outpatient care with close follow-up. Risk factors reviewed without detail: past suicide attempts reported in earlier years, a sedative use disorder, depression, the months after childbirth, and the low mood that can follow stopping a stimulant. Barbiturates are dangerous in overdose, so means safety is part of the plan: she agreed to take the unused capsules from earlier prescriptions to a pharmacy take-back at the next visit, to keep the current supply in a locked box, and to receive no more than seven days at a time. No alcohol with the barbiturate. A written safety plan was made with her, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in her phone. Safety is reviewed at every visit. This is synthetic and does not convert historical behavior into a current finding. **S**

## Assessment

1. Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills; status draft. **S**
2. Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills; status draft. **S**
3. Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence; status draft. **S**
4. Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants; status draft. **S**
5. Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania; status draft. **S**

## Plan

- Safe prescribing of controlled drugs: one prescriber and one pharmacy, a prescription drug monitoring program check before every controlled-substance prescription, a written shared treatment agreement, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused capsules. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Addiction medicine consultation to confirm the diagnoses, plan a safe barbiturate withdrawal and taper, and advise on stopping the stimulant. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Insomnia: cognitive behavioral therapy for insomnia as first-line treatment, adapted to late performances (a fixed wake time, a wind-down routine after shows, sleep restriction only after the taper is stable), with a sleep diary; no new hypnotic. Guideline: Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016) **S**
- Depression and anxiety: PHQ-9 and GAD-7 at each visit, sertraline, weekly psychotherapy, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, means safety and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Nutrition and weight without stigma: regular meals and snacks around rehearsals, a dietitian visit, no weight-loss target and no dieting drugs, and screening for disordered eating. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Contraception that barbiturates do not weaken: medroxyprogesterone injection every 13 weeks, after a negative pregnancy test, with an intrauterine device as an alternative. Guideline: U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024) **S**
- Naloxone not prescribed: she takes no opioid, has no opioid prescription in the monitoring program, her urine test shows no opioids or fentanyl, and all her pills come from a pharmacy; naloxone does not reverse a barbiturate overdose. To be offered at once if an opioid is ever prescribed or any pill comes from outside a pharmacy. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Work: taper steps scheduled away from major performances, a written plan for late nights and travel, and letters she controls. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
